100% tevredenheidsgarantie Direct beschikbaar na betaling Zowel online als in PDF Je zit nergens aan vast
logo-home
Summary BMS44 Mitochondrial Disease Drug Development (BMS44 Radboud University) €3,99   In winkelwagen

Samenvatting

Summary BMS44 Mitochondrial Disease Drug Development (BMS44 Radboud University)

 19 keer bekeken  0 keer verkocht

This summary includes extensive notes and important figures of all 12 lectures of the course given in 2021

Voorbeeld 3 van de 30  pagina's

  • 24 februari 2021
  • 30
  • 2020/2021
  • Samenvatting
Alle documenten voor dit vak (1)
avatar-seller
jessiehendricks
BMS44 Mitochondrial disease drug development
Radboud university, Biomedical sciences master’s course 2021




Syllabus by Jessie Hendricks




Pagina | 1

,Inhoud
Course content and learning goals ......................................................................................................... 3
The structure and function of the OXPHOS system .............................................................................. 4
LE1 Introductory Lecture .................................................................................................................... 4
LE2 The structure and function of the mitochondrial OXPHOS system ............................................ 5
LE3 Introduction proteomics and complexomics .............................................................................. 6
PR1 Practicum ..................................................................................................................................... 7
Cell biological and clinical consequences of mitochondrial defects ..................................................... 7
LE 4 Morphofunction .......................................................................................................................... 7
LE5 Clinical aspects ............................................................................................................................. 8
LE6 Biochemical analysis in OXPHOS disorders ............................................................................... 11
The mitochondrial genome and proteome with special reference to the OXPHOS system .............. 13
LE7 Establishing the mitochondrial proteome................................................................................. 13
PR2 Practicum ................................................................................................................................... 15
LE8 Mitochondrial genome .............................................................................................................. 15
WG1 Critical reading + preparation presentation ........................................................................... 18
IL1 Presentation 1 ............................................................................................................................. 18
Drug development for mitochondrial diseases ................................................................................... 19
LE9 Drug development; general and mitochondrial targets ........................................................... 19
LE10 C. Elegans as an innovative model to probe mitochondrial function .................................... 23
LE11 Instruction WG2 Drug target profile........................................................................................ 26
WG2 Drug profile .............................................................................................................................. 27
LE12 Clinical traits ............................................................................................................................. 27
IL2 Presentation 2 ............................................................................................................................. 30
Final week ............................................................................................................................................. 30
IL3 Question hour ............................................................................................................................. 30
Exam .................................................................................................................................................. 30




Pagina | 2

, Course content and learning goals
Most of the cells' energy comes in the form of ATP, which, under conditions of high energy demand, is
primarily produced by mitochondrial oxidative phosphorylation (OXPHOS). To adequately respond to
changes in cellular ATP demand, the OXPHOS system maintains a stable, inwardly-directed
electrochemical H+ gradient across the inner mitochondrial membrane, the potential energy of which
is used to drive ATP synthesis. The OXPHOS system is composed of 5 multi-protein enzyme complexes
which are built from more than 80 different proteins with the aid of multiple complex-specific
assembly factors. Defects in genes that encode these structural proteins and assembly factors give rise
to a plethora of OXPHOS dysfunction disorders for which currently no cure exists. However,
dysfunction of the OXPHOS system is not only observed in many inborn errors of metabolism but is
also associated with more common pathologic conditions, such as Alzheimer’s disease, Parkinson’s
disease, cancer, cardiac disease, diabetes, epilepsy, Huntington’s disease, and obesity. Moreover, a
progressive decline in the expression of mitochondrial genes is a central feature of normal human
aging. The term “mitochondrial medicine” refers to approaches that have been developed to manage
mitochondrial dysfunction and, directly or indirectly, its consequences. In the past decade, the analysis
of monogenic mitochondrial diseases has considerably advanced our understanding of the cell
biological consequences of mitochondrial dysfunction. In this module we will learn how this
understanding contributes to the rational design of intervention strategies for mitochondrial
dysfunction.

After completion of the course, students are able to
1. Apply basic bioinformatics techniques to obtain a better understanding of the mitochondrial
OXPHOS process at a molecular level.
2. Identify a disease-causing molecular defect from complexome profiling data.
3. Critically evaluate a scientific publication on mitochondrial DNA.
4. Apply acquired knowledge about drug development to design a drug target profile.




Pagina | 3

Voordelen van het kopen van samenvattingen bij Stuvia op een rij:

Verzekerd van kwaliteit door reviews

Verzekerd van kwaliteit door reviews

Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!

Snel en makkelijk kopen

Snel en makkelijk kopen

Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.

Focus op de essentie

Focus op de essentie

Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!

Veelgestelde vragen

Wat krijg ik als ik dit document koop?

Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.

Tevredenheidsgarantie: hoe werkt dat?

Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.

Van wie koop ik deze samenvatting?

Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper jessiehendricks. Stuvia faciliteert de betaling aan de verkoper.

Zit ik meteen vast aan een abonnement?

Nee, je koopt alleen deze samenvatting voor €3,99. Je zit daarna nergens aan vast.

Is Stuvia te vertrouwen?

4,6 sterren op Google & Trustpilot (+1000 reviews)

Afgelopen 30 dagen zijn er 67232 samenvattingen verkocht

Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen

Start met verkopen
€3,99
  • (0)
  Kopen